1. Contingent liabilities
 
 (a) Claims against the company not acknowledged as debt
 
                                              (Amount in Rs.)
 
 Particulars                                As at         As at
                                     31 March 2012    31 March 2011
 
 Excise and service tax matters         2,665,077        2,665,077
 
 (b) Guarantees                                 (Amount in Rs.)
 
 Particulars                                As at           As at
                                       31 March 2012   31 March 2011
 
 In respect of bank guarantees         18,341,417       14,152,892
 
 (c) Others
 
 The Company had received a notice from Bruhat Bangalore Mahanagara
 Palike (BBMP) on 23 February 2011 demanding a payment of Rs. 113,328,767
 as Land Improvement Charges towards its factory land. The Company fled
 a writ petition on 28 May 2011 before the High Court of Karnataka
 challenging the levy of the improvement charges and obtained an interim
 stay order on 2 June 2011 against cancellation by BBMP of the Khata of
 the factory land, if the improvement charges were not paid.
 
 On 20 October 2011, the Company has received a notice from BBMP to stop
 the construction of the tablet production facility pending the
 construction license from BBMP. The Company''s writ petition fled in the
 High Court of Karnataka challenging the notice and the High Court
 allowed the construction by granting a stay. Subsequent to the year
 end, on 20 April 2012, the high court has passed an order quashing the
 levy of differential improvement charges on different dimension of
 property. The Company is awaiting for a certified copy of the order.
 
 2. As a measure of extra and abundant caution, the Company undertook
 a voluntary recall of steril products manufactured at its plant
 amounting to Rs. 26,826,401, following AstraZeneca''s Global quality audit
 As a precautionary measure, the Company also voluntarily suspended
 production temporarily to review manufacturing practices at the plant
 resulting in a temporary interruption of supplies. Sales for the year
 ended 31 March 2012 is net of the returns received on account of the
 voluntary recall.
 
 3. Research expenditure (including depreciation) amounting to Rs.
 14,412,244 (previous period: Rs. 32,177,960 incurred during the year has
 been charged to the respective heads of account in the statement of
 proft and loss.
 
 4. During the year, a First Information Report (FIR) was fled by the
 Central Bureau of Investigation agains the Company on 23 February 2012
 wherein it is alleged that the Company submitted a false affdavit wit
 respect to rates quoted by the Company to the institution (Directorate
 of Health Services, Delhi). It is furthe alleged that unknown offcers
 of the Directorate of Health Services, Delhi (DHS) and unknown offcials
 of th Company conspired to cancel the recovery proceedings by DHS. The
 Company is fully cooperating with th ongoing investigations.
 
 5.Related parties
 
 (i) Names of related parties and description of relationship:
 
 Holding company AstraZeneca Pharmaceuticals AB, Sweden
 
 Holding company of AstraZeneca Pharmaceuticals AB, Sweden
 
 AstraZeneca AB, Sweden
 
 Holding company of AstraZeneca AB, Sweden AstraZeneca Treasury Limited,
 United Kingdom
 
 Ultimate holding company AstraZeneca Plc, United Kingdom
 
 Fellow subsidiaries
 
 AstraZeneca SDN Bhd, Malaysia;
 
 AstraZeneca Singapore Pte Ltd, Singapore;
 
 AstraZeneca Philippines;
 
 AstraZeneca Belgium;
 
 AstraZeneca India Private Limited;
 
 PT AstraZeneca Indonesia;
 
 AstraZeneca Pty Ltd, Australia;
 
 AstraZeneca China;
 
 AstraZeneca Pharmaceuticals LP USA;
 
 AstraZeneca Thailand; and
 
 PR Pharmaceuticals Inc
 
 Key management personnel
 
 - Managing Director Anandh Balasundaram
 
 - Directors Ian Brimicombe
 
 Bhasker V Iyer (resigned w.e.f 23 February 2010) Mr. Luigi Felice
 Lacorte (appointed w.e.f 25 March 2010) Francis McNamara III (resigned
 w.e.f 30 September 2010) Ruby Lau (appointed w.e.f 10 November 2011)
 
 6. Segment reporting
 
 The primary segments of the Company are its business segments as
 follows:
 
 (i) Healthcare - The Company engages in the manufacture, trading and
 sale of pharmaceutical products.
 
 (ii) Clinical trial services - The Company renders clinical trial
 services on pharmaceuticals products to its group companies.
 
 (iii) Co-promotional services – The Company renders co-promotion
 services for pharmaceuticals products to its customers.
 
 The accounting policies consistently used in the preparation of the
 financial statements are also applied to record revenue and expenditure
 in individual segments.
 
 Revenue and direct expenses in relation to segments are categorised
 based on items that are individually identifable to that segment, while
 other costs, wherever allocable, are apportioned to the segments on an
 appropriate basis. Certain income and expenses are not specifcally
 allocable to individual segments as the underlying assets and services
 are used interchangeably. The Company therefore believes that it is not
 practicable to provide segment disclosures relating to such income and
 expenses and accordingly such expenses are separately disclosed as
 ''unallocated'' and directly charged against total income.
 
 Assets and liabilities in relation to segments are categorised based on
 items that are individually identifable to that segment. Certain assets
 and liabilities are not specifcally allocable to individual segments as
 these are used interchangeably. The Company therefore believes that it
 is not practicable to provide segment disclosures relating to such
 assets and liabilities and accordingly these are separately disclosed
 as ''unallocated''. Assets are primarily located in India.
 
 Clinical trial services and co-promotion services do not qualify as
 separate segments as defned in AS – 17 – ''Segment Reporting'' and hence
 have been disclosed as others.
 
 7. Leases
 
 The Company is obligated under non-cancellable operating leases for
 residential and offce premises.  Total rental expense under
 non-cancellable operating leases amounted to Rs. 6,010,958 (previous
 period: Rs. 1,809,856 ) for the year ended 31 March 2012.
 
 The Company is also obligated under cancellable lease for residential
 and offce premises, which are renewable at the option of lessor and
 lessee. Total rental expense under cancellable operating lease entered
 amounted to Rs. 38,276,322 (previous period: Rs. 38,715,700 ) for the year
 ended 31 March 2012.
 
 Further the Company is obligated under operating lease agreements for
 vehicles. Total lease rental expense under the said agreement amounted
 to Rs. 1,857,704 (previous period: Rs. 2,096,998) for the year ended 31
 March 2012.
 
 8. Dues to micro and small enterprises
 
 The Ministry of Micro, Small and Medium Enterprises has issued an offce
 memorandum dated 26 August 2008 which recommends that the Micro and
 Small Enterprises should mention in their correspondence with its
 customers the Entrepreneurs Memorandum Number as allocated after fling
 of the Memorandum in accordance with the ''Micro, Small and Medium
 Enterprises Development Act, 2006 (''the Act''). Accordingly, the
 disclosure in respect of the amounts payable to such enterprises as at
 31 March 2012 has been made in the financial statements based on
 information received and available with the Company. Further in view of
 the Management, the impact of interest, if any, that may be payable in
 accordance with the provisions of the Act is not expected to be
 material. The Company has not received any claim for interest from any
 supplier as at the balance sheet date.
 
 9. Gratuity plan
 
 The Company has the following defned Gratuity plan.
 
 Leaving service benefit:
 
 Eligibility for benefit: Every employee who has completed 3 years or
 more of service would be eligible for gratuity benefit as per the terms
 of the Trust Deed.
 
 For Non-Management staff:
 
 15 days salary for each year of service, subject to maximum limit
 specifed as per the Gratuity Act, 1972 .
 
 Normal retirement benefit, death and disability benefit: For Management
 staff:
 
 One month''s salary last drawn by member for each year of service,
 without limit.
 
 10. Provident fund
 
 The Company contributed Rs. 29,086,637 towards provident fund during the
 year ended 31 March 2012
 
 The guidance on implementing AS 15, Employee benefits (revised 2005)
 issued by Accounting Standard Boards that benefits involving employer
 established provident funds, which require interest shortfalls to be
 recompensed are to be considered as defned benefits plans. The Actuarial
 Society of India has issued the fnal guidance for measurement of
 provident fund liabilities for the year ended 31 March 2012. The
 actuary has accordingly provided a valuation and based on the below
 provided assumptions there is no shortfall as at 31 March 2012.
 
 11. Management believes that the Company has established a
 comprehensive system of maintenance of information and documents as
 required by the transfer pricing legislation under sections 92-92F of
 the Income Tax Act, 1961. Management is of the opinion that its
 international transactions are at arm''s length so that the aforesaid
 legislation will not have any impact on the financial statements,
 particularly on the amount of tax expenses and that of provision for
 taxation.
 
 12. The Board of Directors of the Company at its meeting held on 11
 May 2012, approved the financial statements for the year ended 31 March
 2012. The Board of Directors, at the said meeting, also recommended a
 fnal dividend of Rs. 3.50 on equity share of Rs. 2 each for the year ended
 31 March 2012. The payment of the said dividend is subject to the
 approval of the shareholders at the Annual General Meeting.
 
 13 A foreign national was appointed as Whole time Director of the
 Company during the year. The Company has fled an application with the
 Central Government under the Companies Act, 1956 seeking approval for
 the appointment of, and remuneration payable to, the said Director. The
 application is pending before the Central Government.
 
 14 The comparatives in the financial statements for the period ended
 31 March 2011 are for the period from 1 January 2010 to 31 March 2011
 i.e. 15 months period. Since the current year numbers are for a year
 i.e.  twelve months period, the previous period fgures may not be
 strictly comparable to the current year fgures.
 
 15 Till the year ended 31 March 2011, the Company was using
 pre-revised Schedule VI to the Companies Act 1956, for preparation and
 presentation of its financial statements. During the year ended 31 March
 2012, the revised Schedule VI notifed under the Companies Act 1956, has
 become applicable to the Company.  The Company has reclassifed previous
 period fgures to conform to this year''s classifcation. The adoption of
 revised Schedule VI does not impact recognition and measurement
 principles followed for preparation of financial statements. However, it
 significantly impacts presentation and disclosures made in the financial
 statements, particularly presentation of balance sheet.